Table 25a, Baseline characteristics of patients in trials in the therapy review: Tachyphylaxis to LABA - Exercise-Induced Bronchoconstriction and Asthma

Warning: The NCBI web site requires JavaScript to function. more...

Author Year	Age (mean±SD) Males: N (%)	Asthma status	Pulmonary function (%predicted FEV₁/mean±SD)	Max % fall FEV₁ (mean±SD)	Smoking status: N (%)	Atopic status: N (%)	ICS history: N (%)
Formoterol vs. placebo
Garcia⁵⁴ 2001	F: 22.8±6.1 P: 25.4±5.2 F: 3/10 (30) P: 5/9 (56)	Stable x 1 mo and throughout trial	F: 104.4±19.4 P: 97.7±13.4	Control ECT F: 21.5±10.0 P: 18.11±10.0	NR	NR	F: 3/10 (30) P: 3/9 (33.3)
Salmeterol vs. placebo
Nelson⁵⁵ 1998	29±8.9 9/20 (45)	Stable but with mixed severity	93±13.4	Control ECT 24±8.9	Non-smokers	Mixed	6/20 (30)
Ramage⁵⁷ 1994	25.8±5.0 8/12 (66.7)	Stable mild	105.7±20.5	Placebo ECT 34.8±17.0	Non-smokers	7/12 (58.3)	3/12 (25)
Selvaggio⁵⁸ 2003	Range 6–16 NR	NR	NR	Placebo ECT 36.6±7.6	NR	NR	NR
Simons⁵⁹ 1997	13.1±1.3 7/16 (43.8)	Stable	93.4±12.7	Placebo ECT 24±12	NR	16/16 (100)	16/16 (100)
Salmeterol vs. montelukast
Edelman⁵³ 2000	Salm: 26; range 15‐ 46 M: 26.5, range 15–46 Salm: 54/94 (57) M: 46/97 (47)	Stable with range of severity	Salm: 88.0±13.5 M: 87.1±11.2	Control ECT Salm: 36.6±12.3 M: 37.0±11.5	Non-smokers ≥1yr	NR	None
Villaran⁶⁰ 1999	All: 27±5.4 Salm: 45/95 (47) M: 53/102 (52)	Stable mild	Salm: 87.2±14 M: 86.6±13.7	Control ECT Salm: 30.5±10.5 M: 33.3±12.1	Past: 170/197 (86) Never 27/197 (13.7)	NR	Salm: 6/95 (6.3) M: 14/102 (13.7)

: ECT = exercise challenge test; F = formoterol; FEV₁ = forced expiratory volume in 1 second; M = montelukast; mo = month(s); NR = not reported; P = placebo; salm = salmeterol; SD = standard deviation

Exercise-Induced Bronchoconstriction and Asthma.

Evidence Reports/Technology Assessments, No. 189.

Dryden DM, Spooner CH, Stickland MK, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.